{
    "clinical_study": {
        "@rank": "43358", 
        "arm_group": [
            {
                "arm_group_label": "1", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "2", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "3", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "4", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "Objective of this study is to evaluate the safety, tolerability, pharmacokinetics and\n      preliminary pharmacodynamic effects of multiple doses of Gantenerumab in subject with mild\n      to moderate AD."
        }, 
        "brief_title": "A Multiple-dose Study of Gantenerumab in Japanese Alzheimer's Disease Patients", 
        "condition": "Alzheimer's Disease", 
        "condition_browse": {
            "mesh_term": "Alzheimer Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Have a diagnosis of probable AD dementia, based on NINCDS/ADRDA criteria\n\n          -  Meet DSM-IV criteria for Dementia of the Alzheimer type\n\n          -  MMSE score : 16 to 26 etc.\n\n        Exclusion Criteria:\n\n          -  Meet the exclusion criteria of MRI at screening.\n\n          -  A history of significant neurodegenerative diseases or dementia  other than\n             Alzheimer's disease.\n\n        etc."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "28", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 5, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01656525", 
            "org_study_id": "JP22431", 
            "secondary_id": "JapicCTI-121849"
        }, 
        "intervention": [
            {
                "arm_group_label": "1", 
                "description": "75 mg subcutaneous doses every 4 weeks for 24 weeks", 
                "intervention_name": "Gantenerumab", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "2", 
                "description": "105 mg subcutaneous doses every 4 weeks for 24 weeks", 
                "intervention_name": "Gantenerumab", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "3", 
                "description": "225 mg subcutaneous doses every 4 weeks for 24 weeks", 
                "intervention_name": "Gantenerumab", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "4", 
                "description": "subcutaneous doses every 4 weeks for 24 weeks", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "August 6, 2013", 
        "location": [
            {
                "contact": {
                    "email": "clinical-trials@chugai-pharm.co.jp", 
                    "last_name": "Akira Chiba"
                }, 
                "facility": {
                    "address": {
                        "city": "Kansai", 
                        "country": "Japan"
                    }, 
                    "name": "Kansai region"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "clinical-trials@chugai-pharm.co.jp", 
                    "last_name": "Akira Chiba"
                }, 
                "facility": {
                    "address": {
                        "city": "Kanto", 
                        "country": "Japan"
                    }, 
                    "name": "Kanto region,"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "clinical-trials@chugai-pharm.co.jp", 
                    "last_name": "Akira Chiba"
                }, 
                "facility": {
                    "address": {
                        "city": "Kyushu", 
                        "country": "Japan"
                    }, 
                    "name": "Kyushu region"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "clinical-trials@chugai-pharm.co.jp", 
                    "last_name": "Akira Chiba"
                }, 
                "facility": {
                    "address": {
                        "city": "Toakai", 
                        "country": "Japan"
                    }, 
                    "name": "Tokai region"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "clinical-trials@chugai-pharm.co.jp", 
                    "last_name": "Akira Chiba"
                }, 
                "facility": {
                    "address": {
                        "city": "Tohoku", 
                        "country": "Japan"
                    }, 
                    "name": "Tohoku region"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Multi-center, Multiple-ascending Dose, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Safety, Tolerability and Pharmacokinetics of Gantenerumab Following Subcutaneous Injection in Japanese AD Patients", 
        "overall_contact": {
            "email": "clinical-trials@chugai-pharm.co.jp", 
            "last_name": "Akira Chiba"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Ministry of Health, Labor and Welfare Board Affiliation:JAPAN", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of participants with Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "36 weeks"
            }, 
            {
                "measure": "Pharmacokinetic parameters of Gantenerumab in plasma", 
                "safety_issue": "Yes", 
                "time_frame": "36 weeks"
            }, 
            {
                "measure": "CSF/plasma ratios of Gantenerumab.", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline, Day183"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01656525"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline in plasma  Abeta", 
                "safety_issue": "No", 
                "time_frame": "Baseline,Day183"
            }, 
            {
                "measure": "Change from baseline in plasma and CSF tau", 
                "safety_issue": "No", 
                "time_frame": "Baseline,Day183"
            }, 
            {
                "measure": "Change from baseline in Mini-Mental State Examination (MMSE) and Alzheimer's disease assessment scale cognitive behaviors (ADAS-Cog).", 
                "safety_issue": "No", 
                "time_frame": "Baseline,Day85, 197, 253"
            }
        ], 
        "source": "Chugai Pharmaceutical", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chugai Pharmaceutical", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}